(PRESS RELEASE) EVERGREEN, CO — Canopy Growth Corporation, a world-leading diversified cannabis and hemp company, announced that two CBD studies have been published in industry-leading peer-reviewed journals.
Both studies signify important research on the topic of CBD use in pets. The 28-day study in dogs is a step towards better understanding the long-term impact of daily CBD use and how it interacts in the canine body, while the feline study is just the beginning of Canopy Growth’s work in understanding CBD use in cats. The completion of these studies demonstrates Canopy Growth’s continued commitment to CBD science and industry-leading investment into research.
Further explaining the objective and importance of these studies Dr. Justyna Kulpa, PhD, senior scientist Canopy Growth, stated: “While cannabinoids, particularly CBD, are of growing veterinary research interest, there is a lack of data, especially in cats. We sought to address relevant research gaps through well-designed blinded and placebo-controlled studies. The results lend to our continued exploration of the potential therapeutic applications of CBD in companion animals.”
About the Randomized and Placebo-Controlled 28-Day Safety and Pharmacokinetics Study on Cannabidiol in Healthy Dogs
Conducted in the Autumn of 2019, The Randomized and Placebo-Controlled 28-Day Safety and Pharmacokinetics Study on Cannabidiol in Healthy Dogs looked at the pharmacokinetics and long-term tolerability of CBD in dogs given daily over the course of 28 days.
The randomized, blinded, placebo-controlled trial saw five groups of dogs receive one of four doses of CBD or Placebo oil orally once daily for 28 days and found that repeated CBD administration was well tolerated by dogs, with no veterinary reported clinically important abnormal findings or severe adverse events.
The full study and its findings were published in the May 2021 issue of American Journal of Veterinary Research and can be read here.
About The Safety and Tolerability of Escalating Cannabinoid Doses in Healthy Cats
Conducted in the Summer of 2018, The Safety and Tolerability of Escalating Cannabinoid Doses in Healthy Cats examined feline tolerability and pharmacokinetics when CBD, THC or CBD plus THC was administered in escalating amounts.
The randomized, blinded, placebo-controlled trial saw 20 healthy adult cats randomly placed into five treatment groups, each group was then given up to 11 escalating doses of the trial formulations orally with at least 3 days between consecutive doses and found that both CBD and THC were generally well-tolerated by healthy cats, with only mild adverse reactions reported.
The full study and its findings were published in the March 2021 issue of American Association of Feline Practitioners’ Journal of Feline Medicine and Surgery and can be read here.
Speaking on the study findings, Dr. Robert Menardi, DVM, director of veterinary educational and technical services at Canopy Growth, stated: “Both of the most recently completed studies are trailblazing in the field of veterinary CBD research. We are confident this and subsequent research will provide valuable knowledge for the veterinary community and consumers.”
To ensure all products meet the highest quality standards, Canopy Growth continues to work closely with the veterinary and academic community, regulatory authorities and leading scientists.
Scientists conducted both studies’ animal care and experimental procedures under protocols approved by the research facility’s Institutional Animal Care and Use Committee in accordance with the Principles of the Animals for Research Act, as well as guidelines from the Canadian Council on Animal Care and the Veterinary Drug Directorate of Health Canada. All Canopy Growth studies are conducted safely, ethically and responsibly.